Generics Manufacturing, Stockpiling Before IP Expiries Could Boost EU
This article was originally published in The Pink Sheet Daily
Executive Summary
If generics firms were permitted to manufacture and stockpile products ahead of IP expiries, it’s estimated they could add almost €4.5 billion ($6.3 billion) to the EU economy over nine years.
You may also be interested in...
European Generics Need To Climb Into Niches, Huddle Together For Growth
The current situation for Europe’s generic medicines manufacturers is at best uncomfortable due to significant pricing pressures and increasing competition, but the reality is that it is likely to get far worse.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.